NLS Pharmaceutics Ltd. and Kadimastem Ltd. Merger Approval and Closing Date

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced the receipt of Nasdaq approval for their proposed merger, which is expected to close on October 30, 2025. The combined company will be named NewcelX Ltd. and will trade under the symbol 'NCEL' on the Nasdaq Capital Market. The merger involves a share exchange where Kadimastem shareholders will hold 84.4% of the combined company, while NLS shareholders will retain 15.6%. The final exchange ratio was determined on September 26, 2025, and the delisting of Kadimastem's shares from the Tel Aviv Stock Exchange is expected on October 31, 2025. The merger will allow NewcelX to advance its clinical programs, including AstroRx® for ALS and IsletRx for diabetes.